- Home
- NAGE vs SLGL Comparison
NAGE vs SLGL Comparison
Compare NAGE & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | SLGL |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.0M | 254.1M |
| IPO Year | 2010 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NAGE | SLGL |
|---|---|---|
| Price | $3.06 | $63.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $16.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 346.5K | 52.7K |
| Earning Date | 05-06-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.82 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $129,423,000.00 | N/A |
| Revenue This Year | $16.51 | N/A |
| Revenue Next Year | $14.58 | $223.84 |
| P/E Ratio | $33.44 | ★ N/A |
| Revenue Growth | ★ 29.95 | N/A |
| 52 Week Low | $2.87 | $27.00 |
| 52 Week High | $10.05 | $97.97 |
Technical Indicators
Market Signals| Indicator | NAGE | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 47.46 | 45.68 |
| Support Level | $2.95 | $62.21 |
| Resistance Level | $3.61 | $67.85 |
| Average True Range (ATR) | 0.07 | 3.08 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 48.94 | 58.87 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.